# Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide

> **NCT01300793** · PHASE1 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 6 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- B-cell Lymphoma

## Interventions

- **DRUG:** Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide

## Key facts

- **NCT ID:** NCT01300793
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2011-07
- **Final completion:** 2012-04
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** closed for low accrual and no data is available.
- **Last updated:** 2012-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300793, "Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01300793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*